Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies Journal Article
| Authors: | Cassidy, J.; Saltz, L. B.; Giantonio, B. J.; Kabbinavar, F. F.; Hurwitz, H. I.; Rohr, U. P. |
| Article Title: | Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies |
| Abstract: | Background Bevacizumab is frequently combined with 5-Xuorouracil-based chemotherapy for patients with metastatic colorectal cancer (mCRC). The relative beneffit of bevacizumab in older patients has not been widely studied and is of interest. Patients and methods This retrospective analysis used data from three first-line randomized controlled studies and one second-line randomized controlled study of bevacizumab plus chemotherapy in medically Wt (Eastern Cooperative Oncology Group performance status 0 or 1) patients with mCRC. Overall survival (OS) and on-treatment progression-free survival (PFS) were assessed in patients aged <65, ≥65, and ≥70 years. Results were compared using unstratiWed hazard ratios (HRs). Grade 3-5 adverse events were also assessed. Results Bevacizumab statistically signiWcantly improved PFS [HR 0.58; 95% confidence interval (CI) 0.49-0.68] and OS (HR 0.85; 95% CI 0.74-0.97) in patients aged ≥65 years; patients aged ≥70 years had similar improvements. BeneWts were consistent across the studies, irrespective of setting, bevacizumab dose, or chemotherapy regimen. Increases in thromboembolic events were observed in patients aged ≥65 and ≥70 years in the bevacizumab group compared with the control group, mainly as a result of increases in arterial thromboembolic events. No other substantial age-related increases in grade 3-5 adverse events were observed. Conclusions In medically Wt older patients, bevacizumab provides similar PFS and OS beneWts as in younger patients. |
| Keywords: | adolescent; adult; controlled study; aged; middle aged; retrospective studies; overall survival; clinical trial; mortality; fistula; angiogenesis inhibitor; bevacizumab; fluorouracil; hypertension; capecitabine; disease free survival; chemotherapy; colorectal cancer; metastasis; controlled clinical trial; bleeding; randomized controlled trial; randomized controlled trials as topic; age factors; drug effect; pathology; retrospective study; age; irinotecan; monoclonal antibody; colorectal neoplasms; wound healing; antibodies, monoclonal; thromboembolism; colorectal tumor; folinic acid; neoplasm metastasis; oxaliplatin; angiogenesis inhibitors; digestive system perforation; congestive heart failure; proteinuria; artery thrombosis; venous thromboembolism; older patients; metastatic colorectal cancer; pooled analysis; abscess; artery thromboembolism |
| Journal Title: | Journal of Cancer Research and Clinical Oncology |
| Volume: | 136 |
| Issue: | 5 |
| ISSN: | 0171-5216 |
| Publisher: | Springer |
| Date Published: | 2010-05-01 |
| Start Page: | 737 |
| End Page: | 743 |
| Language: | English |
| DOI: | 10.1007/s00432-009-0712-3 |
| PUBMED: | 19904559 |
| PROVIDER: | scopus |
| PMCID: | PMC2841755 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 8" - "Export Date: 20 April 2011" - "CODEN: JCROD" - "Source: Scopus" |
